The Diary of a CEOTyna Moore: Microdosing GLP-1 quietly heals the brain
Moore reframes Ozempic as a regenerative tool at micro doses; she explains how GLP-1 calms brain inflammation, heals the gut, and helped her chronic pain.
CHAPTERS
- 4:00 – 14:00
Defining Naturopathic Medicine and Metabolic Root Causes
Moore explains what a naturopathic physician is, how her training differs from conventional MDs, and why she focuses on metabolic health as the root of many chronic illnesses rather than on disease labels. She describes her mentor’s influence and the concept of getting patients into a ‘healing state’ so that regenerative therapies and the body’s own systems can work.
- •Naturopathic training: 4‑year medical program, boards, focus on root‑cause and homeostasis.
- •Contrast with allopathic medicine’s algorithmic, diagnosis‑plus‑drug model.
- •Metabolic health as the ability to properly assimilate proteins, fats, and carbohydrates.
- •Insulin resistance and prediabetes normalized over decades, with a 15–20 year window for intervention.
- •Clinical emphasis on optimizing hormones, nutrition, and lifestyle before advanced procedures like stem cells or PRP.
- 14:00 – 32:00
A Personal Case Study: Saving Her Mother from Crohn’s Decline
Moore recounts how she nearly missed her mother’s Crohn’s disease until it was life‑threatening, then used an aggressive naturopathic and regenerative protocol to pull her out of crisis. She later added microdosed semaglutide, describing dramatic improvements in gut stability, joint pain, cognition, and anxiety.
- •Mother presented with severe diarrhea, weight loss, gray appearance, hair loss—ultimately diagnosed as Crohn’s with family history.
- •Moore avoided immediate colonoscopy fearing flora disruption and hospital complications.
- •Used off‑label regenerative therapies and referred her mother to a naturopath for ongoing drug management.
- •Tiny doses of semaglutide later normalized bowels, reduced joint pain, improved color, weight, and cognition.
- •Mother reported a marked drop in stress and anxiety; Moore attributes this to reduced neuroinflammation via gut–brain effects.
- 32:00 – 48:00
Moore’s Own Health Journey: Autoimmunity, Pain, and GLP‑1 Discovery
Moore shares her lifelong history of stomach aches, anxiety, and chronic pain, culminating in severe psoriatic arthritis and near‑suicidal desperation by 2021. After many failed interventions, she began researching GLP‑1 and neuroinflammation, leading her to experiment with semaglutide on herself, with unexpectedly profound results.
- •Childhood and teen years marked by gut issues, anxiety, sudden severe depression after moving to low‑light Oregon.
- •Later recognizes underlying psoriatic arthritis and importance of light/vitamin D on immune function.
- •By 2021 her spine was fusing, pain was debilitating, and standard naturopathic/functional tools were failing.
- •Breakout psoriasis confirmed psoriatic arthritis; she tried naltrexone, exosomes, etc. with only transient relief.
- •Prompted by her podcast producer to examine Ozempic, she googled ‘GLP‑1 and neuroinflammation’ and found extensive literature contradicting media panic.
- 48:00 – 1:08:00
What GLP‑1 and Ozempic Actually Are: Peptides, Mechanisms, and Effects
The conversation shifts into GLP‑1 biology, explaining peptides, how semaglutide mimics endogenous GLP‑1, and its multiple actions on appetite, gastric emptying, insulin secretion, and brain function. Moore underscores that many obese and diabetic individuals are GLP‑1 deficient and that modern gut health compromises natural GLP‑1 production.
- •Peptides are chains of amino acids; GLP‑1 is a peptide hormone made in gut L‑cells and brain.
- •Semaglutide is bioidentical to GLP‑1 with lipid modification for longer half‑life.
- •Functions: central appetite reduction, slowed gastric motility at higher doses, glucose‑dependent insulin secretion, improved insulin sensitivity.
- •Many people have damaged guts and GLP‑1‑deficient states, especially with obesity, T2D, fatty liver.
- •Moore’s first low‑dose trial led to rapid improvement in brain fog, anxiety, pain, and spontaneous increase in movement and exercise.
- 1:08:00 – 1:20:00
Beyond Weight Loss: Regeneration, Cancer, Kidneys, and the Brain
Moore outlines research she believes shows GLP‑1 agonists are broadly regenerative and protective: reducing cardiovascular events, improving kidney outcomes, aiding beta‑cell regeneration in early type 1 diabetes, and possibly lowering certain cancer risks. She stresses that many of these benefits appear independent of weight loss.
- •System‑by‑system review papers show GLP‑1 benefits on brain inflammation, cardiovascular tissues, muscle, bone, joints, testes, and sperm.
- •SELECT trial: ~20% reduction in major cardiovascular events in overweight non‑diabetics on semaglutide; follow‑up analysis suggests benefits independent of weight loss.
- •FLOW trial in chronic kidney disease stopped early to offer semaglutide to controls due to strong benefit.
- •Studies suggest possible pancreatic beta‑cell regeneration in early type 1 diabetes.
- •Observational data tie GLP‑1 use to reduced obesity‑related cancers versus insulin or no GLP‑1, though causality isn’t proven.
- 1:20:00 – 1:29:00
Muscle, ‘Muscle Loss’ Myths, and the Importance of Strength Training
Addressing fears that Ozempic causes muscle wasting, Moore differentiates between lean mass and true muscle tissue, arguing that rapid caloric restriction—via any method—costs muscle and that GLP‑1s may actually improve muscle health when used properly alongside strength training and adequate protein.
- •Any severe caloric restriction (diets, bariatric surgery, high‑dose GLP‑1) typically loses 20–35% lean mass, which includes organs, tendons, and brain—not just muscle.
- •Metabolically unhealthy muscle is ‘marbled’ with fat; GLP‑1s help clear this fatty infiltrate and improve insulin sensitivity.
- •Data suggest GLP‑1 agonists promote muscle protein synthesis and improved muscle perfusion, especially in aging muscle.
- •Moore insists on non‑negotiable strength training and protein prioritization to preserve/build muscle while on GLP‑1s.
- •She views muscle as a central ‘organ of longevity’ and key to metabolic and hormonal resilience.
- 1:29:00 – 1:43:00
Microdosing vs. Standard Dosing: How Much, How Often, and Why
Using a physical demo, Moore contrasts conventional prefilled GLP‑1 pen dosing (0.25 mg escalating to ~2.4–2.5 mg weekly) with her microdosing approach using compounded semaglutide. She describes titrating based on symptom thresholds, cycling on/off to resensitize receptors, and always combining with other therapies and lifestyle changes.
- •Standard protocol: start at 0.25 mg/week, double dose every 4 weeks to ~2.4–2.5 mg; maintain indefinitely.
- •Moore views starting dose as too high for metabolically optimized or smaller patients and unnecessary for many.
- •Microdosing: uses compounded formulations and insulin syringes to deliver fractions of 0.25 mg, individualized to effect, often weekly or less frequently.
- •Aims to stay just below GI or depressive side effects; later cycles patients off and on to avoid receptor saturation.
- •Warns against self‑titration and urges people to work with knowledgeable doctors, ideally through compounding pharmacies or at least by holding at lower pen doses while optimizing lifestyle.
- 1:43:00 – 1:51:00
GLP‑1, Dopamine, and Addiction: Quieting the ‘Noise’
Moore explains how GLP‑1 signaling in the brain affects dopaminergic reward pathways, not just appetite hormones like ghrelin and leptin. She shares anecdotal and early research hints of reduced alcohol abuse, smoking, compulsive eating, and even compulsive online shopping in patients on GLP‑1s, framing the drugs as reducing hedonic ‘noise’ and restoring control.
- •GLP‑1 is produced in multiple brain regions with receptors throughout, affecting hypothalamus and dopamine pathways.
- •Patients describe losing constant food preoccupation and gaining mental space to choose what and when to eat.
- •Animal studies show semaglutide‑treated rats stop seeking hyper‑palatable sugar‑fat‑salt mixes and choose basic chow instead.
- •Reports of decreased desires for alcohol, cigarettes, cocaine, and even compulsive shopping and porn consumption.
- •Moore stresses the opportunity to couple this ‘quiet’ period with building new, healthy habits that become hard‑wired via neuroplasticity.
- 1:51:00 – 2:00:00
Fertility Crisis, PCOS, and Metabolic Dysfunction
The discussion widens to global fertility trends and the role of metabolic dysfunction, PCOS, and sperm decline. Moore argues that GLP‑1’s impact on metabolic health and PCOS makes it a potentially powerful tool amid rising IVF dependence, but only alongside major environmental and lifestyle corrections.
- •Projections that by 2100 about 97% of countries won’t be reproducing at replacement rates; sperm counts projected to approach zero mid‑century.
- •PCOS framed as a metabolic syndrome with high androgens, low progesterone, insulin resistance; a leading cause of female infertility.
- •Moore claims GLP‑1s can reverse many PCOS features (citing her daughter’s case and others) by correcting metabolic dysfunction.
- •Men’s sperm volume, motility, and testicular function are also impacted by metabolic health; GLP‑1 may help but data are still early.
- •She views successive generations of metabolically compromised parents epigenetically programming their offspring for earlier, worse metabolic disease.
- 2:00:00 – 2:07:00
The Toxic Soup: Food, Microbiome, Toxins, and Social Decay
Moore paints a broad picture of the modern ‘toxic soup’: ultra‑processed foods engineered for overconsumption, widespread chemical exposure, antibiotic‑induced microbiome disruption, sedentary living, light deprivation, and loneliness. She argues that these drivers make metabolic dysfunction nearly inevitable and that GLP‑1s are only one part of a much larger corrective effort.
- •Food supply adulterated in the 1990s with hyper‑palatable sugar‑fat‑salt blends; most people now eat similar or fewer calories but worse quality.
- •Environmental and cosmetic toxins, especially in women’s beauty routines, are significant endocrine and metabolic disruptors.
- •Overuse of antibiotics profoundly disrupts microbiomes, affecting immune and metabolic health across the lifespan.
- •COVID policies worsened isolation, collapsed community structures, shut gyms and churches, and harmed mental and physical health.
- •She reiterates that everyone has a ‘toxic bucket’ that eventually overflows into metabolic dysfunction and chronic disease.
- 2:07:00 – 2:18:00
Six Pillars for a Pain‑Free, Metabolically Healthy Life
Drawing from her book, Moore outlines practical pillars—strength training, movement, nutrition, sleep, mindset, and hormetic stressors like heat—that she believes are foundational for resolving chronic pain and disease. She argues that without these, no drug, including GLP‑1s, will produce durable health.
- •Strength training: essential for muscle mass, insulin sensitivity, and resilience; even older adults can build or maintain muscle.
- •Movement: at least three 10‑minute walks daily; integrate with sunlight exposure to reinforce circadian rhythm.
- •Nutrition: prioritize ~30 g animal protein per meal and colorful whole foods; don’t start by ‘taking away’ but by adding nutrient density.
- •Sleep: protect bedtime/wake time consistency, reduce blue light, remove phones/TVs from bedroom, fix circadian rhythm via light.
- •Mindset: commit to the ‘quest’ of health, focusing on process not just outcome; reframe traits like neurodivergence as potential superpowers.
- •Heat therapy: sauna or hot baths to induce heat shock proteins, move lymph and blood, and calm immune activation.
- 2:18:00 – 2:30:00
Risk, Reward, and the Ethics of Using GLP‑1
Moore addresses concerns that we lack long‑term safety data on microdosing and reiterates the need for risk–benefit analysis. She argues that the risks of staying in chronic inflammation and metabolic collapse often outweigh the theoretical risks of low‑dose GLP‑1, especially when monitored, while warning strongly against DIY experimentation.
- •She emphasizes that the most alarming side effects are seen at high doses in high‑risk patients already on the edge of pancreatitis, gallstones, or gastroparesis.
- •Believes tiny doses are less concerning than high chronic doses; nonetheless calls for close monitoring, labs, and symptom tracking.
- •Stresses informed consent: explaining mechanism, known data, uncertainties, and alternative options to patients.
- •Explicitly discourages listeners from self‑dosing obtained online without medical supervision.
- •Advocates working with functional, longevity, or compounding‑savvy physicians when possible, or at minimum, holding at low pen doses and aggressively changing lifestyle.
- 2:30:00
Closing Reflections: Responsibility, Curiosity, and Telling Unpopular Truths
In closing, Moore and Bartlett discuss intellectual humility, seeking knowledge, and being willing to challenge consensus. Moore says she’s proudest of choosing a hard path to tell early, unpopular truths for patients’ benefit and urges audiences to independently verify claims rather than following influencers or headlines.
- •Encourages constant learning and critical thinking: verify sources, read studies, don’t outsource judgment.
- •Admits the toll of public pushback but remains committed to sharing what she believes can help people.
- •Frames her role as translating complex science into practical steps ordinary people can apply.
- •Bartlett positions the conversation as hypothesis‑generating rather than prescriptive, stressing the need for ongoing research.
- •Moore emphasizes that progress often starts with anecdotes and hypotheses that later get tested and refined.
